Multilineage dysplasia without increased blasts identifies a poor prognosis subset of myelodysplastic syndromes

TO THE EDITOR
According to the French-American-British (FAB) criteria, myelodysplastic syndromes (MDS) are classified into five groups: refractory anemia (RA), RA with ring sideroblasts (RARS), chronic myelomonocytic leukemia (CMML), RA with excess of blasts (RAEB) and RAEB in leukemic transformation (RAEB-t).
1 While RAEB and RAEB-t have a uniformly poor prognosis, a great variability in survival is observed within the other three groups. Over the past decade, different scoring systems have been proposed to obtain a better prognostic characterization of individual MDS patients, but imprecision persists with these analyses. [2] [3] [4] [5] [6] [7] Rosati et al 8 reviewed 60 patients for whom the original diagnosis was RA, RARS, MDS 'unclassifiable' or RAEB, and identified 18 cases characterized by multilineage hematopoietic dysplasia, but with an insufficient number of blood or bone marrow blasts to meet the FAB criteria for RAEB, and too few monocytes for a diagnosis of CMML. This subset of MDS, named 'refractory cytopenia with multilineage dysplasia' (RCMD), had a short survival time (24 months), more similar to that of RAEB (18 months) than RA/RARS (107 months). In a recent issue of Leukemia, Matsuda et al 9 identified a poor prognosis group using two distinct dysplastic changes (Pseudo-Pelger-Huet anomalies and micromegakaryocytes).
After Rosati's publication, we reviewed all cases of RA, RARS and RAEB observed in our institution between 1985 and 1995 and for whom peripheral blood smears, bone marrow aspirate slides and adequate clinical information were available. One hundred and three cases have been re-examined (52 with RA, 14 with RARS and 37 with RAEB) and 32 patients (25 previously classified as RA and seven as RARS) fulfilled the criteria proposed by Rosati et al for RCMD diagnosis. The clinical and hematological findings of the three groups are shown in Table 1 .
Cumulative survival is shown in Figure 1 . Median survival was 101.6 months for RA+RARS, 31.1 for RCMD and 17.2 for RAEB. The cause of death was related to MDS (ie due to leukemia, infection or hemorrhagic complications) in 2/14 (14.3%) of RA+RARS, 7/19 (36.8%) of RCMD and 15/32 (46.9%) of RAEB patients. Disease progression, defined as evolution to higher grade of MDS or acute leukemia, is shown in Figure  2 . Among 32 patients with RCMD, eight progressed to RAEB and five developed overt leukemia from 6 to 21 months after diagnosis. Among 34 patients with RA+RARS, two progressed to RAEB and only one developed leukemia after 110 months from diagnosis, while 20 of 37 RAEB patients underwent leukemic transformation within 37 months from diagnosis.
Our observation confirms the previously reported findings that multilineage dyspoiesis characterizes about one-half of MDS cases classified as RA and RARS according to FAB, and that it identifies a subgroup of patients with poor clinical outcome. [10] [11] [12] In our series, introduction of this new subgroup of MDS greatly improved the prognostic value of FAB classification. In fact, median survival for the 66 patients classified Correspondence: CL Balduini; Fax: 39 382 52 5222 Received 25 November 1997; accepted 10 July 1998
Figure 1
Cumulative proportion survival in the three patient subgroups.
Figure 2
Time to disease evolution (progression to RAEB or overt leukemia) in the three patient subgroups.
as RA+RARS according to FAB was 52.1 months, while it jumped to 101.6 months after enucleation of the 32 subjects with RCMD.
In conclusion, our study supports the Rosati proposal of establishing a new MDS subgroup, the RCMD, which is characterized by strong propension toward progression and short survival time despite the absence of increased blast count.
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